List of Excipients in Branded Drug OMTRYG

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Trygg Pharma Inc	OMTRYG	omega-3-acid ethyl esters	61112-001	.ALPHA.-TOCOPHEROL
Trygg Pharma Inc	OMTRYG	omega-3-acid ethyl esters	61112-001	GELATIN
Trygg Pharma Inc	OMTRYG	omega-3-acid ethyl esters	61112-001	GLYCERIN
Trygg Pharma Inc	OMTRYG	omega-3-acid ethyl esters	61112-001	WATER

Omtryg Excipient Strategy and Commercial Opportunities in Omega-3 Prescription Therapy

Last updated: August 3, 2026

Omtryg is a prescription omega-3-acid ethyl ester product for adults with severe hypertriglyceridemia, generally defined as triglycerides of at least 500 mg/dL. Its commercial value depends less on novel pharmacology than on formulation quality, oxidation control, dose burden, tolerability, and differentiation from generic omega-3 products and competing agents such as Lovaza, Vascepa, and Epanova. The strongest development opportunities are concentrated in high-concentration capsules, improved sensory performance, lower pill burden, and formulations that preserve bioequivalence while reducing manufacturing complexity.

What is Omtryg and how is it formulated?

Omtryg contains omega-3-acid ethyl esters, primarily ethyl eicosapentaenoate and ethyl docosahexaenoate. The product is supplied as a 1-gram soft gelatin capsule and is used with diet to reduce triglyceride levels in adults with severe hypertriglyceridemia.[1]

The commercial formulation has four main components:

Formulation element	Function	Commercial significance
EPA and DHA ethyl esters	Active pharmaceutical ingredients	Require high purity, oxidation control, and consistent fatty-acid composition
Gelatin shell	Encapsulates the oil fill	Controls mechanical integrity, moisture transfer, and consumer acceptability
Glycerin	Plasticizer	Determines shell flexibility and stability
Sorbitol and purified water	Shell humectant and processing components	Affect shell brittleness, dissolution, and storage performance

The product label identifies gelatin, glycerin, sorbitol, and purified water among the inactive ingredients.[1] Because the active fill is an unsaturated lipid mixture, excipient selection must be evaluated together with oxygen exposure, peroxide formation, aldehyde generation, shell permeability, and long-term capsule stability.

What excipient strategy is most suitable for Omtryg?

The preferred strategy is a low-oxygen, low-moisture softgel system that protects the omega-3 ethyl ester fill without introducing unnecessary formulation complexity.

Oxidation control

Omega-3 fatty acids are highly vulnerable to oxidation. The principal quality risks include:

• Peroxide and hydroperoxide formation
• Secondary oxidation products, including aldehydes
• Off-odor and fishy aftertaste
• Loss of active fatty-acid content
• Degradation-related changes in dissolution and bioavailability

The highest-value excipient opportunity is therefore an integrated antioxidant and packaging system. Potential approaches include tocopherol-based antioxidants, oxygen-scavenging secondary packaging, nitrogen flushing, low-headspace filling, and high-barrier blister or bottle systems.

An antioxidant should not be added solely to improve shelf life. Its compatibility with the specific EPA/DHA mixture, gelatin shell, manufacturing temperature, and regulatory filing must be demonstrated. A formulation with fewer excipients but stronger oxygen control may have a better commercial profile than a heavily protected formulation with higher manufacturing cost.

Shell optimization

The gelatin shell affects stability, swallowing, rupture, dissolution, and leakage. Glycerin and sorbitol concentrations can be adjusted to control:

• Shell elasticity
• Brittleness under low humidity
• Tackiness under high humidity
• Seal strength
• Drying time
• Dissolution behavior

A harder shell may improve handling and reduce leakage but can delay rupture. A softer shell may improve swallowability but increase deformation during shipping. The commercial target is a shell that maintains integrity across the labeled storage range without materially changing drug release.

Fish-derived gelatin can also create labeling and sourcing issues. A bovine or porcine gelatin alternative may expand supplier options, while a non-animal shell could support vegetarian positioning. Those changes would require comparability work and may create new risks involving oxygen transmission, moisture permeability, dissolution, and capsule-machine compatibility.

Taste and odor management

Although Omtryg is swallowed rather than chewed, fishy reflux and aftertaste can reduce adherence. The most practical controls are:

1. Purified and deodorized active ingredients
2. Reduced oxidation during filling and storage
3. High-barrier packaging
4. Capsule surface treatment or secondary coating
5. Smaller capsules or multi-unit dosing formats

Flavoring the liquid fill is generally less attractive because flavorants can introduce compatibility and stability issues. Odor prevention is usually more durable than odor masking.

What formulations are protected by Omtryg-related intellectual property?

The relevant intellectual-property categories are likely to include the active composition, fatty-acid purity, capsule formulation, manufacturing process, and therapeutic use. For an omega-3 ethyl ester product, the most commercially relevant claims typically concern:

• Defined EPA-to-DHA ratios
• Minimum omega-3 purity
• Limits on saturated and monounsaturated fatty acids
• Oxidation specifications
• Softgel compositions
• Encapsulation and drying processes
• Use in patients with severe hypertriglyceridemia
• Combination treatment with lipid-lowering agents

A formulation patent is commercially stronger when it claims a measurable product characteristic that competitors cannot easily design around. Examples include a narrow oxidation profile, a defined release profile, a specific fatty-acid distribution, or a capsule structure linked to improved stability.

A broad claim to omega-3 ethyl esters is less defensible after multiple products and generic manufacturing processes enter the market. Process patents may still have value where the process improves purification, deodorization, concentration, or stability and is difficult to replicate without infringing steps.

When did Omtryg lose regulatory exclusivity?

Omtryg was approved by the FDA in 2014 under NDA 022363.[1] Its regulatory exclusivity period was separate from any patent protection. Because Omtryg was not a new molecular entity in the conventional sense, the principal regulatory barrier was expected to be a shorter period of marketing exclusivity rather than the five-year exclusivity associated with a new active ingredient.

The key distinction is:

Protection type	Relevance to Omtryg
New chemical entity exclusivity	Generally not the central protection for an omega-3 ethyl ester product
Three-year clinical investigation exclusivity	Potentially relevant to the approved formulation or indication
Orange Book patents	May delay or complicate ANDA approval if valid and enforceable
Patent-term restoration	Potentially relevant only if statutory requirements were met
Regulatory exclusivity for an orphan indication	Not the primary commercial framework for Omtryg

Any current generic-entry analysis requires review of the FDA Orange Book, approved labeling, listed patents, and litigation records. FDA’s Orange Book identifies patents and exclusivity associated with approved drug products but does not determine whether a listed patent is valid or infringed.[2]

What generic entry risks exist for Omtryg?

Generic competition is structurally significant because omega-3-acid ethyl ester products use established active ingredients, oral softgel delivery, and conventional excipients. A generic applicant can pursue an abbreviated new drug application if it can demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA standards.

The main technical barriers are:

• Variability in EPA and DHA composition
• Batch-to-batch oxidation differences
• Food-effect sensitivity
• Capsule shell differences
• Dissolution and disintegration performance
• Bioequivalence testing for a complex lipid mixture
• Fish-allergen and source-material documentation

Omega-3 products can be more difficult to characterize than simple small-molecule tablets because the active ingredient is a mixture of related fatty-acid ethyl esters. The generic sponsor must control the composition sufficiently to meet the reference-product standard while avoiding unnecessary cost.

A competing product can pursue several routes:

Entry route	Commercial effect
Direct generic of Omtryg	Highest substitution risk where an AB-rated product is available
Alternative prescription omega-3 product	Competes through dose, EPA/DHA composition, or clinical positioning
OTC fish-oil supplement	Applies price pressure but does not automatically substitute at the prescription level
Re-esterified triglyceride product	Competes on absorption, tolerability, and consumer preference
EPA-only product	Differentiates through composition and cardiovascular positioning

Which companies are challenging Omtryg commercially?

Omtryg competes with several product classes rather than a single direct rival.

Lovaza

Lovaza also contains omega-3-acid ethyl esters and has a similar therapeutic role in severe hypertriglyceridemia. The main competitive variables are brand recognition, payer coverage, generic availability, capsule burden, and price.

Vascepa

Vascepa contains icosapent ethyl, an EPA-only product. Its differentiated active composition and cardiovascular outcomes data give it a distinct commercial position. It is not a direct formulation substitute for an EPA/DHA ethyl ester product, although it competes for physician attention and payer budgets.

Epanova

Epanova used omega-3 carboxylic acids rather than conventional ethyl esters. Its formulation approach illustrates the value of changing lipid chemistry to affect absorption and dosing, although clinical and commercial outcomes remain separate from excipient performance.

OTC fish-oil products

OTC products compete strongly on price and availability. They usually have greater variability in active composition, quality specifications, and regulatory status. Prescription products can differentiate through standardized EPA/DHA content, manufacturing controls, labeling, and reimbursement.

How can excipients create commercial opportunities?

High-concentration capsules

The clearest opportunity is reducing the number of capsules required per day. A 1-gram capsule contains only a fraction of omega-3 active material, so patients may need multiple capsules daily. A higher-load capsule, if technically feasible, could improve adherence and reduce packaging, dispensing, and shipping costs.

The principal constraints are capsule volume, fill viscosity, shell strength, leakage, dissolution, and dose uniformity.

Improved stability and shelf life

A formulation with lower peroxide growth and reduced secondary oxidation may support longer shelf life, fewer recalls, and better patient experience. This opportunity can be protected through a combination of formulation claims, manufacturing controls, and validated packaging.

Low-odor prescription products

A deodorized, low-oxidation product could target patients who discontinue omega-3 therapy because of reflux or fishy taste. This is a practical commercial distinction, although it must be supported by sensory and stability data rather than marketing language alone.

Alternative capsule materials

A non-gelatin or gelatin-reduced capsule could address dietary, religious, and sourcing preferences. The opportunity is commercially attractive but technically more demanding because many alternative shells have different oxygen and moisture transmission characteristics.

Combination products

An omega-3 formulation combined with a statin or another lipid-lowering agent could reduce pill burden. Combination products create regulatory and intellectual-property opportunities but also increase development cost, interaction testing, labeling complexity, and payer scrutiny.

How strong is the Omtryg patent estate?

The patent estate should be assessed by claim scope rather than patent count. The strongest claims would cover a formulation or manufacturing feature that is both measurable and difficult to reproduce without using the claimed technology.

A practical diligence framework is:

Patent category	Strength indicator	Main vulnerability
Composition	Narrow, reproducible EPA/DHA and purity limitations	Design-around through composition changes
Formulation	Stability or release benefit tied to specific excipients	Obviousness and routine optimization arguments
Manufacturing	Non-obvious purification or deodorization process	Competitor may use a different process
Method of use	Defined patient population and dosing regimen	Label carve-out and clinical overlap
Packaging	Specific barrier structure linked to stability	Weak if treated as routine packaging optimization

Patent strength also depends on remaining term, prosecution history, claim construction, infringement evidence, and whether a generic applicant has filed a Paragraph IV certification.

What is the Orange Book and Paragraph IV status of Omtryg?

A Paragraph IV certification asserts that an Orange Book-listed patent is invalid, unenforceable, or not infringed. If an ANDA applicant makes that certification and the patent holder files suit within the statutory period, FDA approval may be subject to a 30-month stay, subject to statutory exceptions and court developments.[3]

For Omtryg, the relevant diligence questions are:

• Which patents were listed against NDA 022363?
• Which patents remained unexpired when generic applicants filed?
• Did any applicant submit a Paragraph IV certification?
• Was litigation filed within the statutory period?
• Did the parties reach a settlement?
• Did any agreement include a licensed entry date or authorized generic provision?
• Are any method-of-use patents subject to a Section viii statement or label carve-out?

Patent listings and litigation status can change over time. The FDA Orange Book and federal court records are the controlling sources for current status.[2,4]

What FDA regulatory issues affect Omtryg excipient development?

A reformulated Omtryg product may require a new drug application supplement, a 505(b)(2) application, or an ANDA, depending on the relationship to the reference product and the nature of the change. The regulatory burden rises when the reformulation changes:

• Active ingredient composition
• Fatty-acid ratio
• Capsule shell material
• Release characteristics
• Food effect
• Dose strength
• Labeling or indication

For a generic product, excipient changes must remain within the permissible framework for inactive ingredients and must not alter bioequivalence or product performance. For a reformulated branded product, the sponsor may have greater flexibility but must generate supporting stability, dissolution, safety, and bioavailability data.

USP general chapters, FDA inactive-ingredient information, and product-specific FDA guidance should inform excipient selection and control strategy.[5,6]

What are the most attractive commercial scenarios?

Scenario	Value proposition	Risk level
Low-cost direct generic	Captures volume through substitution	High price erosion
Premium high-concentration product	Reduces pill burden	Moderate technical and regulatory risk
Low-odor branded reformulation	Improves adherence and differentiation	Moderate clinical proof requirement
Alternative-shell product	Expands patient acceptability	Moderate-to-high stability risk
Combination lipid therapy	Reduces pill burden and supports adherence	High development and regulatory risk
Contract-manufactured private-label product	Uses established softgel infrastructure	High competition and lower margins

The most defensible near-term opportunity is a high-concentration, oxidation-controlled softgel with demonstrably improved handling and tolerability. A novel excipient alone is unlikely to create durable value. The commercial advantage must be linked to a patient-relevant outcome, such as fewer capsules, less reflux, improved shelf stability, or lower total treatment cost.

Key Takeaways

• Omtryg is an omega-3-acid ethyl ester prescription product for severe hypertriglyceridemia.
• Its excipient strategy is dominated by oxidation control, softgel integrity, odor management, and packaging.
• Gelatin, glycerin, sorbitol, and purified water are central shell components identified in the product labeling.
• The strongest product-development opportunity is a higher-concentration capsule with controlled oxidation and improved tolerability.
• Generic entry risk is substantial because the active ingredients and softgel platform are established.
• Patent value depends on narrow, technically meaningful claims covering composition, formulation, manufacturing, or stability.
• Orange Book listings, Paragraph IV certifications, litigation, and settlements determine the practical timing of generic entry.
• A novel excipient without a measurable performance advantage is unlikely to support premium pricing.

FAQs

Can Omtryg be reformulated with non-gelatin capsules?

Yes. A non-gelatin shell is technically possible, but the sponsor must establish comparable stability, oxygen transmission, moisture behavior, mechanical strength, dissolution, and bioavailability.

Which antioxidant is best for omega-3 ethyl ester capsules?

Tocopherol-based systems are commonly considered, but the optimal antioxidant depends on the specific EPA/DHA concentrate, impurity profile, manufacturing process, and packaging system. Compatibility and long-term oxidation data determine suitability.

Can an Omtryg generic use different excipients?

A generic may use different inactive ingredients within FDA requirements if the product remains pharmaceutically equivalent and bioequivalent and the excipient differences do not create safety, performance, or labeling issues.

Does a higher EPA concentration automatically create a stronger Omtryg competitor?

No. Higher EPA concentration can reduce dose burden, but commercial value also depends on capsule size, bioavailability, tolerability, oxidation stability, reimbursement, and clinical positioning.

Is Omtryg interchangeable with Vascepa?

No. Omtryg contains EPA and DHA ethyl esters, while Vascepa contains icosapent ethyl, an EPA-only active ingredient. Substitution depends on the product, indication, prescriber intent, payer rules, and FDA-rated therapeutic equivalence.

References

1. U.S. Food and Drug Administration. (2014). Omtryg (omega-3-acid ethyl esters) capsules, prescribing information. FDA.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.

3. U.S. Food and Drug Administration. (2023). Abbreviated new drug application submissions: Refuse-to-receive standards. FDA.

4. U.S. Courts. (n.d.). PACER case locator and federal court records. Administrative Office of the United States Courts.

5. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. FDA.

6. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. USP Convention.